Cargando…
Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
Since the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have b...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834774/ https://www.ncbi.nlm.nih.gov/pubmed/35162875 http://dx.doi.org/10.3390/ijerph19031853 |
_version_ | 1784649266596151296 |
---|---|
author | Bortolini, Miguel Junior Sordi Petriz, Bernardo Mineo, José Roberto Resende, Rafael de Oliveira |
author_facet | Bortolini, Miguel Junior Sordi Petriz, Bernardo Mineo, José Roberto Resende, Rafael de Oliveira |
author_sort | Bortolini, Miguel Junior Sordi |
collection | PubMed |
description | Since the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have been carried out using highly controlled methods with accurate immunological tests, clinical questionnaires did not include questions concerning the physical activity profile among volunteers. It has been well established that physical activity plays a pivotal role in the immune response after vaccination, led by the activation of cytokines, antibodies, and cells. This concept should have been considered when evaluating the efficacy of COVID-19 vaccine candidates, particularly in elderly and obese people. Here, we discuss data from the literature providing strong evidence regarding the importance of analyzing physical activity parameters to improve the accuracy of clinical trials on assessing the efficacy of vaccine candidates. |
format | Online Article Text |
id | pubmed-8834774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88347742022-02-12 Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups Bortolini, Miguel Junior Sordi Petriz, Bernardo Mineo, José Roberto Resende, Rafael de Oliveira Int J Environ Res Public Health Review Since the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have been carried out using highly controlled methods with accurate immunological tests, clinical questionnaires did not include questions concerning the physical activity profile among volunteers. It has been well established that physical activity plays a pivotal role in the immune response after vaccination, led by the activation of cytokines, antibodies, and cells. This concept should have been considered when evaluating the efficacy of COVID-19 vaccine candidates, particularly in elderly and obese people. Here, we discuss data from the literature providing strong evidence regarding the importance of analyzing physical activity parameters to improve the accuracy of clinical trials on assessing the efficacy of vaccine candidates. MDPI 2022-02-07 /pmc/articles/PMC8834774/ /pubmed/35162875 http://dx.doi.org/10.3390/ijerph19031853 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bortolini, Miguel Junior Sordi Petriz, Bernardo Mineo, José Roberto Resende, Rafael de Oliveira Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups |
title | Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups |
title_full | Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups |
title_fullStr | Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups |
title_full_unstemmed | Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups |
title_short | Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups |
title_sort | why physical activity should be considered in clinical trials for covid-19 vaccines: a focus on risk groups |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834774/ https://www.ncbi.nlm.nih.gov/pubmed/35162875 http://dx.doi.org/10.3390/ijerph19031853 |
work_keys_str_mv | AT bortolinimigueljuniorsordi whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups AT petrizbernardo whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups AT mineojoseroberto whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups AT resenderafaeldeoliveira whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups |